These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 30583555)

  • 1. Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy.
    Villani R; Vendemiale G; Serviddio G
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30583555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
    Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K
    J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
    Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
    World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
    Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH
    Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents.
    Zou WY; Choi K; Kramer JR; Yu X; Cao Y; El-Serag HB; Kanwal F
    Dig Dis Sci; 2019 Nov; 64(11):3328-3336. PubMed ID: 31041639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
    Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Achievement of a Sustained Virological Response Either Before or After Hepatectomy Improves the Prognosis of Patients with Primary Hepatitis C Virus-Related Hepatocellular Carcinoma.
    Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Uesaka K
    Ann Surg Oncol; 2019 Dec; 26(13):4566-4575. PubMed ID: 31602577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct-Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Wait-List Progression or Posttransplant Recurrence.
    Piñero F; Boin I; Chagas A; Quiñonez E; Marciano S; Vilatobá M; Santos L; Anders M; Hoyos Duque S; Soares Lima A; Menendez J; Padilla M; Poniachik J; Zapata R; Maraschio M; Chong Menéndez R; Muñoz L; Arufe D; Figueroa R; Mendizabal M; Hurtado Gomez S; Stucchi R; Maccali C; Vergara Sandoval R; Bermudez C; McCormack L; Varón A; Gadano A; Mattera J; Rubinstein F; Carrilho F; Silva M
    Liver Transpl; 2020 May; 26(5):640-650. PubMed ID: 32133773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development of hepatocellular carcinoma in HCV-infected patients treated with DAA: A comprehensive analysis.
    Huang P; Liu M; Zang F; Yao Y; Yue M; Wang J; Fan H; Zhuo L; Wu J; Xia X; Feng Y; Yu R
    Carcinogenesis; 2018 Dec; 39(12):1497-1505. PubMed ID: 30602007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection.
    Hayes CN; Zhang P; Zhang Y; Chayama K
    Viruses; 2018 Sep; 10(10):. PubMed ID: 30274202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C Virus-Related One-Year Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial.
    Kamal A; Metawea M; Omar H; Ghallab M; Kassem A; Naguib H
    J Gastrointest Cancer; 2024 Jun; 55(2):913-923. PubMed ID: 38436921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy.
    Saraiya N; Yopp AC; Rich NE; Odewole M; Parikh ND; Singal AG
    Aliment Pharmacol Ther; 2018 Jul; 48(2):127-137. PubMed ID: 29851093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients.
    Ma L; Liu J; Wang W; Yang F; Li P; Cai S; Zhou X; Chen X; Zhuang X; Zhang H; Cao G
    Future Oncol; 2020 Apr; 16(11):675-686. PubMed ID: 32223423
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end.
    Muzica CM; Stanciu C; Huiban L; Singeap AM; Sfarti C; Zenovia S; Cojocariu C; Trifan A
    World J Gastroenterol; 2020 Nov; 26(43):6770-6781. PubMed ID: 33268960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
    Singal AG; Lim JK; Kanwal F
    Gastroenterology; 2019 Jun; 156(8):2149-2157. PubMed ID: 30878469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
    Adhoute X; Penaranda G; Raoul JL; Sellier F; Castellani P; Oules V; Perrier H; Lefolgoc G; Pol B; Campanile M; Bayle O; Beaurain P; Monnet O; Bourlière M
    Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):368-375. PubMed ID: 29384796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors for hepatocellular carcinoma occurrence or recurrence after direct-acting antiviral agents in patients with chronic hepatitis C.
    Yoshimasu Y; Furuichi Y; Kasai Y; Takeuchi H; Sugimoto K; Nakamura I; Itoi T
    J Gastrointestin Liver Dis; 2019 Mar; 28(1):63-71. PubMed ID: 30851174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hepatitis C-related hepatocellular carcinoma and the treatment with direct-acting antiviral agents].
    Liu X; Gao YH; Niu JQ
    Zhonghua Gan Zang Bing Za Zhi; 2017 Dec; 25(12):944-947. PubMed ID: 29325299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular Carcinoma Occurrence and Recurrence after Antiviral Treatment in HCV-Related Cirrhosis. Are Outcomes Different after Direct Antiviral Agents? A Review.
    Spârchez Z; Mocan T
    J Gastrointestin Liver Dis; 2017 Dec; 26(4):403-410. PubMed ID: 29253056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.